Protein Variants | Comment | Organism |
---|---|---|
additional information | construction of the interfering adenovirus vector, specific short hairpin RNA (shRNA) for the bovine SIRT6 gene are designed, usage of shRNA-399 for SIRT6 gene silencing | Bos taurus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
Cl316,243 | a lipolysis drug, interfers with SIRT6 | Bos taurus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
NAD+ + [protein]-N6-palmitoyl-L-lysine | Bos taurus | - |
nicotinamide + [protein]-L-lysine + 2'-O-palmitoyl-ADP ribose | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Bos taurus | A5D7K6 | Qinchuan calf cattle | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
adipose tissue | - |
Bos taurus | - |
preadipocyte | SIRT6 expression pattern analysis during bovine preadipocyte differentiation, overview | Bos taurus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
NAD+ + [protein]-N6-palmitoyl-L-lysine | - |
Bos taurus | nicotinamide + [protein]-L-lysine + 2'-O-palmitoyl-ADP ribose | - |
? |
Synonyms | Comment | Organism |
---|---|---|
SIRT6 | - |
Bos taurus |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
NAD+ | - |
Bos taurus |
Organism | Comment | Expression |
---|---|---|
Bos taurus | inhibition of SIRT5 significantly promotes SIRT6 expression | up |
General Information | Comment | Organism |
---|---|---|
malfunction | analysis of effects of inhibition of SIRT6 on differentiation and lipid synthesis, and related molecular mechanisms, overview. Overexpression of SIRT6 significantly inhibits the mRNA expression of key adipogenesis genes such as CCAAT enhancer binding protein alpha (CEBPalpha), FABP4, FASN, peroxisome proliferator-activated receptor gamma (PPARgamma), and stearoyl-CoA desaturase (SCD), and promotes the expression of lipolysis genes including lipoprotein lipase (LPL), while interference of SIRT6 obtains the opposite results. The lipolysis drug Cl316,243 interfering with SIRT6 significantly promotes the expression of CEBPalpha, FABP4, FASN, PPARgamma, and SCD, and inhibited the expression of LPL, while overexpression of SIRT6 results in the opposite results | Bos taurus |
metabolism | SIRT6 cooperates with SIRT5 to regulate bovine preadipocyte differentiation and lipid metabolism via the AMPKalpha signaling pathway, feedback synergistic regulation of SIRT5 and SIRT6 on differentiation and lipid deposition. In the differentiation process of bovine preadipocytes, inhibition of SIRT5 significantly promotes SIRT6 expression | Bos taurus |
physiological function | SIRT6 is an ADP-ribosyltransferase and NAD+-dependent deacetylase of acetyl and long-chain fatty acyl groups, playing central roles in lipid and glucose metabolism. It is closely related to the occurrence of diabetes and obesity caused by overnutrition and aging. SIRT6 inhibits bovine preadipocyte differentiation and lipid synthesis, cooperating with SIRT5 to decrease lipid deposition, and repressed cell cycle arrest of preadipocytes. SIRT6 inhibits preadipocyte differentiation and lipid deposition by activating the adenosine monophosphate activated protein kinase alpha (AMPK?) pathway. SIRT6 may promote the proliferation of preadipocytes by inhibiting cell cycle arrest | Bos taurus |